# Nurix Therapeutics share price today (Nurix Therapeutics, Inc., NRIX)

> Nurix Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. NRIX · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/nrix

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $14.84 (+20.6% in a year)
- P/E: 5.5×, against its own history
- Revenue (Aug 2026): ₹0.7 B (+8,426.3% on a year ago)
- Profit (Aug 2026): ₹0.5 B

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Nurix Therapeutics share price today? Nurix Therapeutics, Inc.'s share price was $14.84 at the close on 5 November 2026. It has been moving sideways for 1 week. That is 26.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between $12 and $27, and at that close it sat 17% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 6.3 years the share price moved −23% while the S&P 500 moved +124%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Nurix Therapeutics pay? Nurix Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Nurix Therapeutics on? Nurix Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Nurix Therapeutics profitable? Nurix Therapeutics, Inc. earned ₹0.5 B of net profit in the Aug 2026 quarter. The full FY25 year was a loss of ₹0.3 B. That is 81.7% of the quarter's revenue. The same quarter a year earlier lost ₹0.1 B. 11 of the last 12 reported quarters were loss-making. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Nurix Therapeutics make, and is it growing? Nurix Therapeutics, Inc. reported ₹0.7 B of revenue in the Aug 2026 quarter, +8,426.3% on the same quarter a year earlier. Over 4 years it has grown 29.6% a year on average. The last full year, FY25, came in at ₹0.1 B. The last four reported quarters add to ₹0.7 B. FY25 revenue was ₹0.1 B, +54.0% on the year before. Recent pace: the last four quarters grew +2,070.7% on average, against 29.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +738.8%, against +252.7% a year over the last 8 quarters (accelerating). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Nurix Therapeutics keep? Nurix Therapeutics, Inc. has almost no sales yet: FY25 revenue was ₹0.1 B. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow. ## Is Nurix Therapeutics' profit turning into cash? Nurix Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.2 B of cash, against −₹0.3 B of profit. After ₹0.0 B of spending on assets, free cash was −₹0.3 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Nurix Therapeutics' cash go? Nurix Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Nurix Therapeutics' P/E ratio, and how does it compare with its own history? Nurix Therapeutics, Inc.'s P/E is 5.5×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Nurix Therapeutics business getting better or worse? Nurix Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Nurix Therapeutics earn on its capital? Nurix Therapeutics, Inc. earned a ROE of −49% in FY25. That is up from a low of −72% in FY23. Its return on capital used (ROIC) is left out: on sales this small it reads −52,554%, a number that says nothing useful about the business. ## Does Nurix Therapeutics have too much debt? Nurix Therapeutics, Inc. has total debt of ₹0.1 B against shareholder equity of ₹1.0 B as of Aug 2026, so its debt is 0.07× its equity, which is very little. Year by year, that ratio went from 0.04 in FY21 to 0.10 in FY25. So the returns on this page come from the business, not from borrowed money. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Nurix Therapeutics shareholding pattern? 25.9% of Nurix Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 10.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Nurix Therapeutics from balance-sheet trouble? For Nurix Therapeutics, Inc., the Z-score is 6.13. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 6.13 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Nurix Therapeutics rank in its industry? There is no score against its industry: Nurix Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Nurix Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Nurix Therapeutics in size? Nurix Therapeutics is the 85th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Stoke Therapeutics, Inc., Zenas BioPharma, Inc. and Agios Pharmaceuticals, Inc. Just below it: Generate Biomedicines, Inc., Novavax, Inc. and Absci Corporation. ### Biotechnology companies close in size

1. [Stoke Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/stok) $1.7 billion
2. [Zenas BioPharma, Inc.](https://www.sectoralpha.in/us/stocks/zbio) $1.7 billion
3. [Agios Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/agio) $1.7 billion
4. Nurix Therapeutics, Inc. $1.6 billion
5. [Generate Biomedicines, Inc.](https://www.sectoralpha.in/us/stocks/genb) $1.6 billion
6. [Novavax, Inc.](https://www.sectoralpha.in/us/stocks/nvax) $1.6 billion
7. [Absci Corporation](https://www.sectoralpha.in/us/stocks/absi) $1.6 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Byline Bancorp, Inc.](https://www.sectoralpha.in/us/stocks/by) $1.7 billion · Banks - Regional
2. [Wealthfront Corporation](https://www.sectoralpha.in/us/stocks/wlth) $1.7 billion · Software - Application
3. Nurix Therapeutics, Inc. $1.7 billion
4. [Exzeo Group, Inc.](https://www.sectoralpha.in/us/stocks/xzo) $1.7 billion · Insurance - Diversified
5. [ICF International, Inc.](https://www.sectoralpha.in/us/stocks/icfi) $1.7 billion · Consulting Services

## What else do people ask about Nurix Therapeutics? ### What were Nurix Therapeutics's latest quarterly results? Nurix Therapeutics, Inc. reported revenue of ₹0.7 B and net profit of ₹0.5 B for the Aug 2026 quarter. The operating margin was 83.1%, 1,240.8 percentage points higher than a year earlier (as of 5 November 2026). ### What is Nurix Therapeutics's profit? Nurix Therapeutics, Inc. earned ₹0.5 B of net profit in the Aug 2026 quarter. Full-year FY25 profit was −₹0.3 B. The operating margin was 83.1% in the latest quarter (as of 5 November 2026). ### What is Nurix Therapeutics's market cap? Nurix Therapeutics, Inc.'s market capitalisation is $1.6 B at a stock price of $14.84. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Nurix Therapeutics performing? Nurix Therapeutics, Inc.'s share price has been moving sideways for 1 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Nurix Therapeutics's stock price go up? This page does not forecast Nurix Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $14.84, and it has been moving sideways for 1 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### What could break the Nurix Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Nurix Therapeutics a stock worth studying right now? What the numbers show: Nurix Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.